MedTrace Logo

A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786

NCT03236233 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-12-21

No results posted yet for this study

Summary

This study investigates the safety, tolerability and pharmacokinetics of single and repeat doses of PC786.

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

DRUG

PC786 - Single doses

Safety and tolerability of single doses

DRUG

Placebo - Single doses

Safety and tolerability of single doses

DRUG

PC786 - Repeat doses

Safety and tolerability of repeat doses

DRUG

Placebo - Repeat doses

Safety and tolerability of repeat doses

Sponsors & Collaborators

  • Pulmocide Ltd

    lead INDUSTRY

Principal Investigators

  • Malcolm J Boyce, MBChB, MD · cro

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-21
Primary Completion
2017-12-15
Completion
2017-12-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03236233 on ClinicalTrials.gov